Effect of highly active antiretroviral therapy (HAART) on the natural history of ocular manifestations in HIV-infected children

被引:8
作者
Esposito, S [1 ]
Porta, A [1 ]
Bojanin, J [1 ]
Gualtieri, L [1 ]
Cesati, L [1 ]
Vismara, E [1 ]
Principi, N [1 ]
机构
[1] Univ Milan, Inst Pediat, Fdn IRCCS, Osped Magglore Policlin,Dept Ophthalmol, I-20122 Milan, Italy
关键词
ocular manifestations; HIV; HAART; CMV; children;
D O I
10.1038/sj.eye.6702189
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To determine the effect of highly active antiretroviral therapy (HAART) on the natural history of ocular manifestations in HIV-infected children. Methods All of the HIV- infected children attending the Institute of Pediatrics, University of Milan, Milan, Italy, between 1982 and 2004 were studied. Every 3 months, they were physically examined and underwent indirect fundoscopy conducted by an experienced ophthalmologist; if diagnosed as having eye disease, they were evaluated by the ophthalmologist every week while on specific therapy and monthly thereafter. The clinical and laboratory findings before and after the introduction of HAART were compared. Results The cohort consisted of 117 HIV-infected children (61 males), with a follow-up ranging from 0.09 to 22.31 years (median, 16.33 years). A total of nine cases of ocular involvement (7.7%) were diagnosed between 1983 and 1994, before the introduction of HAART. All nine children died 4-24 months (median, 15 months) after the diagnosis of ophthalmic disease. No case of ocular involvement was observed after the introduction of HAART (P = 0.011 vs before HAART). Conclusion The introduction of HAART has had a significant impact on the natural history of ocular manifestations in HIV-infected children, thus suggesting that a reduction in the frequency of ophthalmologic follow-up should be considered for HAART-treated HIV-infected children with immune reconstitution and no visual symptom.
引用
收藏
页码:595 / 597
页数:3
相关论文
共 12 条
[1]   Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy [J].
Deayton, JR ;
Wilson, P ;
Sabin, CA ;
Davey, CC ;
Johnson, MA ;
Emery, VC ;
Griffiths, PD .
AIDS, 2000, 14 (09) :1163-1170
[2]   Immune restoration disease after antiretroviral therapy [J].
French, MA ;
Price, P ;
Stone, SF .
AIDS, 2004, 18 (12) :1615-1627
[3]   HIV-associated retinopathy in the HAART era [J].
Goldberg, DE ;
Smithen, LM ;
Angelilli, A ;
Freeman, WR .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2005, 25 (05) :633-649
[4]   Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy [J].
Jabs, DA ;
Holbrook, JT ;
Van Natta, ML ;
Clark, R ;
Jacobson, MA ;
Kempen, JH ;
Murphy, RL .
OPHTHALMOLOGY, 2005, 112 (05) :771-779
[5]   Seven years of HAART impact on ophthalmic management of HIV-infected patients [J].
Kahraman, G ;
Krepler, K ;
Franz, C ;
Ries, E ;
Maar, N ;
Wedrich, A ;
Rieger, A ;
Dejaco-Ruhswurm, I .
OCULAR IMMUNOLOGY AND INFLAMMATION, 2005, 13 (2-3) :213-218
[6]   Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy in HIV-infected patients - Natural history and clinical predictors [J].
Lin, DY ;
Warren, JF ;
Lazzeroni, LC ;
Wolitz, RA ;
Mansour, SE .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2002, 22 (03) :268-277
[7]   Immune recovery uveitis in a iatrogenically immunosuppressed patient [J].
Miserocchi, E ;
Modorati, G ;
Brancato, R .
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2005, 15 (04) :510-512
[8]   Decline in the AIDS and death rates in the EuroSIDA study: an observational study [J].
Mocroft, A ;
Ledergerber, B ;
Katlama, C ;
Kirk, O ;
Reiss, P ;
Monforte, AD ;
Knsyz, B ;
Dietrich, M ;
Phillips, AN ;
Lundgren, JD .
LANCET, 2003, 362 (9377) :22-29
[9]  
Moraes Haroldo V Jr, 2002, Curr Opin Ophthalmol, V13, P397, DOI 10.1097/00055735-200212000-00010
[10]   Ocular association of HIV infection in the era of highly active antiretroviral therapy and the global perspective [J].
Ng, WT ;
Versace, P .
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2005, 33 (03) :317-329